NextCell Pharma AB: QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT
NextCell Pharma AB* announces that its subsidiary, QVance AB, has published an article in collaboration with the International Society of Cell and Gene Therapy (ISCT). The article, authored by Dr. Lindsay Davies, CSO at NextCell and co-founder of QVance, was published in Cytotherapy and is based on a global survey examining knowledge on particulates in cell and gene therapy (CGT) products.
QVance, founded by cell therapy developers to support other cell therapy developers, aims to become the leading quality analysis company for CGT in the Nordic region. With NextCell's expertise as a foundation, QVance provides quality control tailored to the industry's specific demands, supporting the development of safe therapies.
Dr. Davies comments:
"It is essential that we, together with regulators and industry, establish unified guidelines for CGT. QVance builds on our solid experience in cell therapy to provide other developers with high-quality, practical solutions."
* NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL